The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to, such as developing better systems to integrate clinical information with molecular data and increased FDA oversight.
The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to.
Bryan Loy, MD, MBA, is optimistic about the future, but recognizes that the issues of accountability and FDA governance are the least of the concerns in the area of diagnostic testing.
Daniel F. Hayes, MD, believes having more consistent regulations by making things harder will actually make things easier to get new markers out.
Francisco J. Esteva, MD, PhD, said better systems need to be developed to integrate the clinical information with molecular data to ensure patients get the appropriate care.
John L. Fox, MD, MHA, is also looking forward to increased FDA oversight, although he added that it will still remain to be seen whether the medical community can ensure the tests are used appropriately so the right patients receive the right treatment.
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
House lawmakers are expected to advance a contracting ban today on 5 Chinese research firms; US government officials temporarily relaxed strict guidelines on how laboratories handle, store, and transport H5N1 bird flu samples; a recent report found that the number of abortions occurring in the US continued to grow despite bans.
Read More